By: Ellen Baron, PhD and Oded Ben-Joseph, PhD, MBA
Big guns may have been fired up this week in the financing world with 6 of 12 Biotech IPOs debuting and raising more than $460M dollars.
This figure however is dwarfed by the value of Merger & Acquisitions announced or offers made within healthcare during June to date — and the month isn’t quite over yet!
These deals continue a string of M&A deals announced since the start of 2018, which is headed for record highs — both in the number of deals and the size of those transactions. Overall, healthcare M&A values surged globally during 2017, rising 27% to $332 billion, while the deal count increased 16%. That very robust activity looks to be continuing in 2018.
We strongly believe that despite the recent activity in the public markets, M&A is a far superior path to return on capital for investors — and these numbers support our views.
As a result, we here at Outcome are looking forward to a busy M&A calendar for the remainder of 2018!
– Advisory Services Practice to Assist Growth-Stage Life Science Companies in Pre-Transaction Preparation and Strategic Corporate Development – August 24, 2022 08:30 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Outcome Capital, a highly specialized life science and healthcare investment banking group, today announced the formal launch of an Advisory Services Practice in response to demand from client […]Read More
Outcome Capital Life Science Market Pulse October 2022 Click to view our LifeSciences Pulse NewsletterDownload